Merck KGaA draws the curtain on newest lipid nanoparticle for mRNA vaccines, turbocharging its annual capacity
With the miracle of mRNA vaccines turning the tide on the pandemic, the spotlight has shifted to tiny engineered fat bubbles, dubbed lipid nanoparticles, that shuttle those drugs into patients’ immune cells. Germany’s Merck KGaA, looking to corner demand for the much-in-need delivery tool is now rolling out a higher-efficiency version months ahead of schedule.
Merck KGaA on Wednesday unveiled a new synthetic cholesterol product for launch, which it said will increase capacity for its lipid delivery tools by 50 times, according to a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.